Bryant E. Fong

Managing Director

Greater China

Mr. Fong joined Burrill & Company in 1998 and has been focused on sourcing, evaluating and investing in biotechnology companies through the Burrill Life Sciences Capital Funds, which combined total almost $1 billion for investments in the life sciences. Mr. Fong currently serves on the boards of directors for FerroKin BioSciences, Neurotech Pharmaceuticals, Nora Pharmaceuticals, Odyssey Thera, TRF Pharma, and Catalyst (observer), Elbion (observer), Logical Therapeutics (observer) and Pharmasset (observer). Prior to joining Burrill & Company, Mr. Fong held positions as a biochemist and molecular biologist with two early stage biotechnology companies located in the San Francisco Bay Area. His research experiences include recombinant protein expression in yeast, development of linear artificial chromosomes, and catalytic RNA technology. Mr. Fong earned his bachelors degree with distinction in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.